MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL‑CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
Retrieved on:
Tuesday, March 3, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Clinical medicine, Medicine, Cancer treatments, Immune system, Antineoplastic drugs, Breakthrough therapy, Merck, Pembrolizumab, Checkpoint inhibitor, RNA activation, Sorafenib, CEBPA, the TIMEPOINT Study, MTL-CEBPA, MiNA Therapeutics
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.
Key Points:
- MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.
- The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.
- The drug candidate is also being investigated in an ongoing multi-centre Phase 1b clinical trial in patients with advanced liver cancer in combination with sorafenib.
- We are excited to take the next step and test MTLCEBPA in additional cancer populations in a potentially synergistic combination with an anti-PD1 checkpoint inhibitor.